Golden
Amgen

Amgen

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company founded in 1980 with headquarters in Thousand Oaks, California.

All edits

Edits on 9 Jul 2019
Golden AI"Crunchbase 2013 Snapshot (C) 2013 https://data.crunchbase.com/docs/2013-snapshot#section-using-the-snapshot"
Golden AI edited on 9 Jul 2019 2:42 pm
Edits made to:
Infobox (+1 properties)
Edits on 30 Apr 2019
Julius John Villarisco"Approved suggestion from source: http://www.twitter.com/amgen"
Julius John Villarisco approved a suggestion from Golden's AI on 30 Apr 2019 11:18 am
Edits made to:
Infobox (+1 properties)
Edits on 25 Apr 2019
Golden AI
Golden AI edited on 25 Apr 2019 12:52 am
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 7 Mar 2019
Sameeha Sulaiman
Sameeha Sulaiman edited on 7 Mar 2019 12:31 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 4 Feb 2019
Golden AI"Import data"
Golden AI edited on 4 Feb 2019 11:09 pm
Edits made to:
Infobox (+1 properties)
People (+1314 cells) (+14400 characters)

People

Name
Role
Related Golden topics

Abid AZAM

Employee



Adam Hardin

Employee



Aditya Nag

Employee



aditya narula

Employee



Ahilaa Kamuthurai

Employee



AKASH ARYA

Employee



Alan Jamijian

Employee



Albert Hidayat

Employee



Alberto Chan

Employee



Alejandro Diaz

Employee



Alekhya Narni

Employee



Aleksander Malinowski

Employee



Alessandro Seveso

Employee



Alex Marzo

Employee



Alex Roman

Employee



Alex Shoshitaishvili

Employee



Alexander Julian Veach

Employee



Alfonso Kondo

Employee



Alfredo Zambonini

Employee



Alice Augustine

Employee



Alina Karimova

Employee



Alix Taffle

Employee



Allen Walker

Employee



Allison S

Employee



Alok Gandhi

Employee



Infobox

Edits on 4 Feb 2019
Golden AI
Golden AI edited on 4 Feb 2019 11:54 am
Edits on 22 Jan 2019
Golden AI
Golden AI edited on 22 Jan 2019 12:59 pm
Edits made to:
Infobox (+4 properties)

Infobox

SIC Code
2,836
CIK Number
318,154
IRS Number
953,540,776
Place of incorporation
Edits on 16 Jan 2019
Golden AI"Import data"
Golden AI edited on 16 Jan 2019 7:54 pm
Edits made to:
Infobox (+2 properties)
Edits on 9 Jan 2019
Golden AI
Golden AI edited on 9 Jan 2019 9:56 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 19 Nov 2018
Melanie Manipula"Approved suggestion from source: http://www.amgen.com/"
Melanie Manipula approved a suggestion from Golden's AI on 19 Nov 2018 9:17 pm
Edits made to:
Infobox (-9 properties)
Edits on 18 Nov 2018
Meredith Hanel
Meredith Hanel edited on 18 Nov 2018 8:57 pm
Edits made to:
Infobox (-9 properties)
Categories (+1 topics)
Edits on 24 Oct 2018
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 24 Oct 2018 3:21 am
Edits made to:
Article (+13/-13 characters)

Article

The following Amgen therapeutics are candidates in Phase III clinical trials: Erenumab for episodic migraine; Aranesp for myelodysplastic syndromes; BLINCYTO for acute lymphoblastic leukemia (ALL); ENBREL for psoriatic arthritis and rheumatoid arthritis remission; IMLYGIC for metastatic melanoma; Kyprolis for multiple myeloma; Prolia for glucocorticoid-induced osteoporosis; Repatha for hyperlipidemia; XGEVA for delay or prevention of bone metastases in breast cancerbreast cancer and also for the treatment of cancer-related bone damage in patients with multiple myeloma; Vectibix for metastatic colorectal cancer (mCRC); Omecamtiv mecarbil for chronic heart failure, and EVENITY for postmenopausal osteoporosis and male osteoporosis.

Edits on 1 Oct 2018
Carla Faraguna
Carla Faraguna edited on 1 Oct 2018 4:19 pm
Edits made to:
Categories (+2 topics)
Edits on 29 Sep 2018
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 29 Sep 2018 8:45 pm
Edits made to:
Article (+6/-6 characters)

Article

The top protein-based therapeutics include Neulasta, Neupogen, Aranesp, Epogen and Enbrel. ENBREL is on the market in the United States to treat rheumatoid arthritis, plaque psoriasis and psoriatic arthritis. Neulasta treats people receiving chemotherapy to reduce infection. Aranesp and EPOGEN are used to treat anemia in different circumstances including chronic kidney disease. Cinacalcet (Sensipar in US and Mimpara in EuropeEurope) is used for secondary hyperparathyroidism with chronic kidney disease. XGEVA is for prevention of skeletal related events in patients with bone metastases from solid tumors. Prolia is used to treat postmenopausal women with osteoporosis at risk of fracture . NEUPOGEN is a recombinant-methionyl human granulocyte colony-stimulating factor (G-CSF) to reduce chance of infection due to low white blood cell count for cancer patients receiving chemotherapy . Aimovig was FDA approved in 2018 and will be marketed in partnership with Novartis as a drug to prevent migraines .

Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 29 Sep 2018 8:44 pm
Edits made to:
Article (+16/-16 characters)

Article

The following Amgen therapeutics are candidates in Phase III clinical trials: Erenumab for episodic migraine; Aranesp for myelodysplastic syndromes; BLINCYTO for acute lymphoblastic leukemia (ALL); ENBREL for psoriatic arthritis and rheumatoid arthritis remission; IMLYGIC for metastatic melanoma; Kyprolis for multiple myelomamultiple myeloma; Prolia for glucocorticoid-induced osteoporosis; Repatha for hyperlipidemia; XGEVA for delay or prevention of bone metastases in breast cancer and also for the treatment of cancer-related bone damage in patients with multiple myeloma; Vectibix for metastatic colorectal cancer (mCRC); Omecamtiv mecarbil for chronic heart failure, and EVENITY for postmenopausal osteoporosis and male osteoporosis.

Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 29 Sep 2018 8:44 pm
Edits made to:
Article (+8/-8 characters)

Article

The top protein-based therapeutics include Neulasta, Neupogen, Aranesp, Epogen and Enbrel. ENBREL is on the market in the United States to treat rheumatoid arthritis, plaque psoriasis and psoriatic arthritis. Neulasta treats people receiving chemotherapy to reduce infection. Aranesp and EPOGEN are used to treat anemia in different circumstances including chronic kidney disease. Cinacalcet (Sensipar in US and Mimpara in Europe) is used for secondary hyperparathyroidism with chronic kidney disease. XGEVA is for prevention of skeletal related events in patients with bone metastases from solid tumors. Prolia is used to treat postmenopausal women with osteoporosis at risk of fracture . NEUPOGEN is a recombinant-methionyl human granulocyte colony-stimulating factor (G-CSF) to reduce chance of infection due to low white blood cell count for cancer patients receiving chemotherapy . Aimovig was FDA approved in 2018 and will be marketed in partnership with NovartisNovartis as a drug to prevent migraines .

Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 29 Sep 2018 8:44 pm
Edits made to:
Article (+13/-13 characters)

Article

The top protein-based therapeutics include Neulasta, Neupogen, Aranesp, Epogen and Enbrel. ENBREL is on the market in the United StatesUnited States to treat rheumatoid arthritis, plaque psoriasis and psoriatic arthritis. Neulasta treats people receiving chemotherapy to reduce infection. Aranesp and EPOGEN are used to treat anemia in different circumstances including chronic kidney disease. Cinacalcet (Sensipar in US and Mimpara in Europe) is used for secondary hyperparathyroidism with chronic kidney disease. XGEVA is for prevention of skeletal related events in patients with bone metastases from solid tumors. Prolia is used to treat postmenopausal women with osteoporosis at risk of fracture . NEUPOGEN is a recombinant-methionyl human granulocyte colony-stimulating factor (G-CSF) to reduce chance of infection due to low white blood cell count for cancer patients receiving chemotherapy . Aimovig was FDA approved in 2018 and will be marketed in partnership with Novartis as a drug to prevent migraines .

Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 29 Sep 2018 8:44 pm
Edits made to:
Article (+22/-22 characters)

Article

Amgen works in discovery, development and manufacturing of human therapeutics for treatment of illnesses in the areas of oncology, hematology, cardiovascular diseasecardiovascular disease, inflammation, bone health, nephrology and neuroscience.

Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 29 Sep 2018 8:44 pm
Edits made to:
Article (+10/-10 characters)

Article

Amgen’s products include the following: Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcetcinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine)and Aimovig.

Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 29 Sep 2018 8:44 pm
Edits made to:
Article (+22/-22 characters)

Article

The top protein-based therapeutics include Neulasta, Neupogen, Aranesp, Epogen and Enbrel. ENBREL is on the market in the United States to treat rheumatoid arthritis, plaque psoriasis and psoriatic arthritis. Neulasta treats people receiving chemotherapy to reduce infection. Aranesp and EPOGEN are used to treat anemia in different circumstances including chronic kidney diseasechronic kidney disease. Cinacalcet (Sensipar in US and Mimpara in Europe) is used for secondary hyperparathyroidism with chronic kidney disease. XGEVA is for prevention of skeletal related events in patients with bone metastases from solid tumors. Prolia is used to treat postmenopausal women with osteoporosis at risk of fracture . NEUPOGEN is a recombinant-methionyl human granulocyte colony-stimulating factor (G-CSF) to reduce chance of infection due to low white blood cell count for cancer patients receiving chemotherapy . Aimovig was FDA approved in 2018 and will be marketed in partnership with Novartis as a drug to prevent migraines .